[go: up one dir, main page]

PL2693216T3 - Sposób diagnozowania lub wstępnego diagnozowania beta-amyloidopatii - Google Patents

Sposób diagnozowania lub wstępnego diagnozowania beta-amyloidopatii

Info

Publication number
PL2693216T3
PL2693216T3 PL13190419T PL13190419T PL2693216T3 PL 2693216 T3 PL2693216 T3 PL 2693216T3 PL 13190419 T PL13190419 T PL 13190419T PL 13190419 T PL13190419 T PL 13190419T PL 2693216 T3 PL2693216 T3 PL 2693216T3
Authority
PL
Poland
Prior art keywords
amyloidopathy
prediagnosis
diagnosis
beta
Prior art date
Application number
PL13190419T
Other languages
English (en)
Inventor
Jens Pahnke
Original Assignee
Immungenetics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immungenetics Ag filed Critical Immungenetics Ag
Publication of PL2693216T3 publication Critical patent/PL2693216T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • C07D279/22[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • C07D279/22[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13190419T 2010-09-07 2011-08-30 Sposób diagnozowania lub wstępnego diagnozowania beta-amyloidopatii PL2693216T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102010044561 2010-09-07
EP13190419.5A EP2693216B1 (de) 2010-09-07 2011-08-30 Verfahren zur Diagnose oder Prädiagnose einer Beta-Amyloidopathie
EP11755294.3A EP2614060B1 (de) 2010-09-07 2011-08-30 Thiethylperazin zur behandlung einer beta-amyloidopathie oder alpha-synucleopathie
PCT/EP2011/064893 WO2012031941A2 (de) 2010-09-07 2011-08-30 2-(R²-THIO)-10-[3-(4-R1-PIPERAZIN-1-YL)PROPYL]-10H-PHENOTHIAZINE ZUR BEHANDLUNG EINER β-AMYLOIDOPATHIE ODER ALPHA-SYNUCLEOPATHIE SOWIE VERFAHREN ZU DEREN DIAGNOSE ODER PRÄDIAGNOSE

Publications (1)

Publication Number Publication Date
PL2693216T3 true PL2693216T3 (pl) 2019-04-30

Family

ID=44645670

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11755294T PL2614060T3 (pl) 2010-09-07 2011-08-30 Tietyloperazyna do leczenia β-amyloidopatii lub α-synukleinopatii
PL13190419T PL2693216T3 (pl) 2010-09-07 2011-08-30 Sposób diagnozowania lub wstępnego diagnozowania beta-amyloidopatii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11755294T PL2614060T3 (pl) 2010-09-07 2011-08-30 Tietyloperazyna do leczenia β-amyloidopatii lub α-synukleinopatii

Country Status (13)

Country Link
US (3) US20130184268A1 (pl)
EP (3) EP3097914A3 (pl)
JP (2) JP6084924B2 (pl)
CN (2) CN106243060A (pl)
BR (1) BR112013005472A2 (pl)
CA (2) CA2870626C (pl)
DE (2) DE102010062810B4 (pl)
DK (2) DK2614060T3 (pl)
ES (2) ES2605705T3 (pl)
MX (1) MX357521B (pl)
PL (2) PL2614060T3 (pl)
RU (2) RU2587154C2 (pl)
WO (1) WO2012031941A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230058533A (ko) 2016-07-25 2023-05-03 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
EP4364801B1 (en) 2018-07-26 2025-11-12 TauRx Therapeutics Management Ltd. Optimised dosage of diaminophenothiazines in populations
CN115279915A (zh) * 2020-03-16 2022-11-01 德瑞生物医药股份有限公司 依托泊苷糖苷、其制备方法及其作为抗癌药物的用途
JP2025501408A (ja) * 2022-01-04 2025-01-17 イムヌジェネティクス アーゲー アルツハイマー型認知症の処置又は予防における使用のための特定の投与量のフェノチアジン化合物
CN119998661A (zh) * 2022-10-18 2025-05-13 免疫基因股份公司 鉴别患有阿尔茨海默氏痴呆或处于发展阿尔茨海默氏痴呆的风险的受试者

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH365379A (de) * 1956-04-18 1962-11-15 Sandoz Ag Verfahren zur Herstellung von neuen, in 3-Stellung mit einer einwertigen Schwefelfunktion substituierten Phenothiazinen
BE568701A (pl) * 1957-06-18
US3621097A (en) * 1970-03-30 1971-11-16 Jan Marcel Didier Aron Samuel Method and compositions for treatment of mental illness
US4471116A (en) * 1982-07-28 1984-09-11 Hoffmann-La Roche Inc. Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
WO1996004915A1 (en) * 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
DK1470818T3 (da) * 2003-04-25 2006-11-20 Neuro3D Anvendelse af Piperazin-phenothiazin-derivater til fremstilling af et medikament med neurobeskyttende og/eller neurotrofiske effekter på CNS og/eller PNS
DE102005014142B4 (de) * 2005-03-23 2006-11-09 Hennig Arzneimittel Gmbh & Co. Kg Pelletförmige Retardzubereitung gegen Schwindel
WO2007062862A2 (en) * 2005-12-02 2007-06-07 Ludwig Maximilians Universität München Use of calmodulin inhibitors for the treatment of neurodegenerative disorders
PT3121169T (pt) * 2006-07-11 2022-05-13 Wista Lab Ltd Processos de síntese e/ou purificação de compostos diaminofenotiazínio
PL2064228T3 (pl) * 2006-11-10 2013-01-31 Cara Therapeutics Inc Syntetyczne amidy peptydowe
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
EA021731B1 (ru) * 2008-04-29 2015-08-31 Фарнекст Новые композиции для лечения болезни альцгеймера
BRPI0911874A2 (pt) * 2008-04-29 2018-05-22 Pharnext composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato
EP2282779B1 (en) * 2008-04-29 2013-03-13 Pharnext New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
CN102573847A (zh) * 2009-05-14 2012-07-11 总医院公司 治疗退化性及缺血性疾病的方法和组合物

Also Published As

Publication number Publication date
RU2016118021A3 (pl) 2020-02-26
EP2614060B1 (de) 2016-08-31
US20150024418A1 (en) 2015-01-22
EP2693216B1 (de) 2018-09-12
CN103237802B (zh) 2017-06-09
JP6084924B2 (ja) 2017-02-22
CA2870626C (en) 2018-08-14
MX2013002612A (es) 2013-08-01
ES2701453T3 (es) 2019-02-22
WO2012031941A2 (de) 2012-03-15
DE102010062810B4 (de) 2014-03-13
EP2614060A2 (de) 2013-07-17
MX357521B (es) 2018-07-12
CA2811454C (en) 2017-03-28
ES2605705T3 (es) 2017-03-15
US20130184268A1 (en) 2013-07-18
DE102010062810A1 (de) 2012-03-08
CA2870626A1 (en) 2012-03-15
JP6426663B2 (ja) 2018-11-21
DK2614060T3 (da) 2017-01-02
US9370523B2 (en) 2016-06-21
EP3097914A2 (de) 2016-11-30
CN106243060A (zh) 2016-12-21
EP2693216A1 (de) 2014-02-05
RU2016118021A (ru) 2018-11-01
JP2017019776A (ja) 2017-01-26
CN103237802A (zh) 2013-08-07
US20150374711A1 (en) 2015-12-31
DE102011053114A1 (de) 2012-03-08
BR112013005472A2 (pt) 2020-11-10
DK2693216T3 (en) 2019-01-14
WO2012031941A3 (de) 2012-09-20
PL2614060T3 (pl) 2017-05-31
RU2587154C2 (ru) 2016-06-20
CA2811454A1 (en) 2012-03-15
RU2013110018A (ru) 2014-10-20
JP2013537881A (ja) 2013-10-07
EP3097914A3 (de) 2016-12-28

Similar Documents

Publication Publication Date Title
ZA201205219B (en) Method for diagnosing the stsate of health of a battery
ZA201209730B (en) Method for increasing the health of a plant
SG184797A1 (en) Q tomography method
GB201001833D0 (en) Method
GB201007353D0 (en) Method
GB201007354D0 (en) Method
GB201004759D0 (en) Method
GB201011513D0 (en) Method
GB201008541D0 (en) Diagnostic methods
GB2486031B (en) Attachment method
GB201011420D0 (en) Method for diagnosis
GB201008719D0 (en) Diagnostic method
GB201006306D0 (en) Method
GB201016161D0 (en) Diagnostic method
AP2013007084A0 (en) Diagnostic method
GB201012148D0 (en) Method
IL227295A0 (en) diagnostic method
PL2693216T3 (pl) Sposób diagnozowania lub wstępnego diagnozowania beta-amyloidopatii
ZA201301498B (en) Diagnostic method
GB201012784D0 (en) Method
GB201010855D0 (en) Method
IL229375A0 (en) A method for diagnosing rheumatoid arthritis
GB201007207D0 (en) Method
GB201007522D0 (en) Method
GB201002732D0 (en) Novel diagnostic method